Retatrutide Phase 3 Trial Enrollment Begins: What We Know So Far
Eli Lilly begins phase 3 enrollment for retatrutide, the triple agonist that achieved 24% weight loss in phase 2 trials.
Eli Lilly has begun enrolling participants for phase 3 clinical trials of retatrutide, the first triple agonist targeting GLP-1, GIP, and glucagon receptors. This follows impressive phase 2 results showing an average 24% body weight loss in participants, surpassing the efficacy of current GLP-1 medications like semaglutide and tirzepatide.
The phase 3 program, called TRIUMPH, will evaluate retatrutide’s safety and efficacy across multiple obesity-related endpoints. The trials are expected to enroll over 5,000 participants worldwide, with preliminary results anticipated in late 2027. If successful, retatrutide could reach the market by 2029, potentially becoming the most effective pharmacological treatment for obesity.
Retatrutide’s unique triple mechanism appears to enhance metabolic effects while minimizing side effects common to single-receptor agonists. Phase 2 data showed comparable gastrointestinal tolerability to existing GLP-1 drugs, with most adverse events being mild to moderate.
The development of retatrutide represents a significant advancement in metabolic medicine and could reshape the competitive landscape of the GLP-1 market. Analysts predict it may capture substantial market share from current leaders if its superior efficacy is confirmed in phase 3 trials. Patients and clinicians alike are watching these developments closely, as retatrutide could offer new hope for individuals who haven’t achieved sufficient results with existing treatments.